A Phase 4 interventional study of Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg and Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg in Essential Hypertension, sponsored by Yuhan Corporation. Active, not recruiting at 15 sites in South Korea. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Essential Hypertension by Yuhan Corporation — 2 open to participants now, 4 under way, 2 of them phase 3. Essential Hypertension · Yuhan Corporation.
Among the 10 studies in Essential Hypertension by Yuhan Corporation, this one is one of 2 that started in 2023, is the only one in phase 4, and was the 3rd registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →2 of the 10 studies in Essential Hypertension by Yuhan Corporation are open now, in 1 country. Recruiting first, the newest first:
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 2 started in 2023.
This study's enrollment of 198 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 221 across the 9 interventional studies, 1,219 across the 1 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.
1 of the studies in Essential Hypertension by Yuhan Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06282549Yuhan CorporationStudy to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Essential Hypertension by Yuhan Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to compare the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination and Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients with Essential Hypertension Uncontrolled by Telmisartan and Amlodipine Combinations
This is a Phase IV, Randomized, Open-label, Superiority, Comparative study evaluating the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination) versus Telmisartan, Amlodipine, and Hydrochlorothiazide in eledrly patient with essential hypertension uncontrolled by Telmisartan and Amlodipine Combinations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with uncontrolled essential hypertension at screening
Exclusion Criteria:
Test results showing the following values at screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Telmisartan/Amlodipine/Chlorthalidonea 40/5/12.5 mg will be orally administered during the study period
Drug: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
Telmisartan/Amlodipine 40/5 mg and Hydrochlorothiazide 25 mg will be orally administered each during study period
Drug: Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Also known as: Truset 40/5/12.5mg
PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Also known as: Twynsta 40/5 mg, Dichlozid 25 mg
Mean Systolic Blood Pressure (MSBP) in nighttime
To evaluate change from baseline in nighttime Mean Systolic Blood Pressure (MSBP) measured by Ambulatory Blood Pressure Monitoring at Week 8
Time frame: Week 8
Mean Systolic Blood Pressure (MSBP) in nighttime
To evaluate change from baseline in nighttime Mean Systolic Blood Pressure (MSBP) measured by Ambulatory Blood Pressure Monitoring at Week 26 if applicable
Time frame: Week 26 if applicable
Mean Diastolic Blood Pressure (MDBP) in nighttime
To evaluate change from baseline in nighttime Mean Diastolic Blood Pressure (MDBP) measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable
Time frame: Week 8 and Week 26 if applicable
Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP) in daytime
To evaluate change from baseline in daytime Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP) measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable
Time frame: Week 8 and Week 26 if applicable
24-hour Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP)
To evaluate change from baseline in 24-hour Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP) measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable
Time frame: Week 8 and Week 26 if applicable
Patients Achieving in nighttime Mean Systolic Blood Pressure (MSBP)
To evaluate the percentage of patients who reached the treatment goal for nighttime Mean Systolic Blood Pressure (MSBP) (\<110/65mmHg) measured by Ambulatory Blood Pressure Monitoring at Week 8
Time frame: Week 8
Mean Sitting Systolic Blood Pressure (MSSBP)/ Mean Sitting Diastolic Blood Pressure (MSDBP)
To evaluate change from baseline in Mean Sitting Systolic Blood Pressure (MSSBP)/ Mean Sitting Diastolic Blood Pressure (MSDBP) measured by the Institution at Week 4, Week 8 and Week 26 if applicable
Time frame: Week 4, Week 8 and Week 26 if applicable
Patients Achieving in Mean Sitting Systolic Blood Pressure (MSSBP)
\- To evaluate the percentage of patients who reached the treatment goal for Mean Sitting Blood Pressure (MSBP) \< 140/90 mmHg measured by the Institution at Week 4, Week 8 and Week 26 if applicable
Time frame: Week 4, Week 8 and Week 26 if applicable
Percentage of patients with decreased Mean Sitting Systolic Blood Pressure (MSSBP) and Mean Sitting Diastolic Blood Pressure (MSDBP).
To evaluate the percentage of subjects with a Mean Sitting Systolic Blood Pressure (MSSBP) decrease of ≥20mmHg and a Mean Sitting Diastolic Blood Pressure (MSDBP) decrease of ≥10mmHg at Week 4, Week 8 and Week 26 if applicable
Time frame: Week 4, Week 8 and Week 26 if applicable
T/P ratio
To evaluate the T/P ratio for systolic/diastolic blood pressure measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable
Time frame: Week 8 and Week 26 if applicable
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Feb 2026, 28 months after the start.
Of 22 phase 4 interventional studies under Essential Hypertension, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 36. This study's planned 28 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.